UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

AVANOS MEDICAL, INC.
Petitioner,

v.

STRATUS MEDICAL, LLC,
Patent Owner.

_____

IPR2024-01209
U.S. Patent No. 10,966,782

_____

PATENT OWNER'S UPDATED MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8, the Patent Owner, Stratus Medical, LLC updates its mandatory notices. Only related-proceedings information is updated at this time. There are no updates to Stratus's real-party-in-interest, counsel, or service information at this time.

Previously Identified Related Matters

The following is an update of the previously identified judicial and administrative matters that may affect or be affected by a decision in this case. *See* Paper 44 (filed Sept. 26, 2025).

(a) IPR2024-01210

On March 6, 2026, the Board entered a final written decision is this case finding all challenged claims of U.S. Patent No. 10,736,688 unpatentable.

(b) IPR2024-01211

On March 6, 2026, the Board entered a final written decision is this case finding all challenged claims of U.S. Patent No. 10,736,688 unpatentable.

(c) IPR2024-01212

On March 5, 2026, the Board entered a final written decision is this case finding all challenged claims of U.S. Patent No. 10,925,664 unpatentable.

(d) U.S. Patent Application No. 17/190,224

This application is a continuation of the ’782 Patent under review in this IPR. The Office issued a final Office Action in this application on October 14, 2025, rejecting all claims for double-patenting and as allegedly obvious over at least Racz and Lee. Stratus filed a response on April 14, 2026. Copies of that Office Action and Response are provided as Exhibits 2047 and 2048, respectively, for the Board’s convenience.

(e) U.S. Patent Application No. 18/378,138

This application is a grandchild continuation of the ’664 Patent under review in IPR2024-01212 and a great grandchild continuation of the ’668 Patent under review in IPR2024-01210 and IPR2024-01211. On December 4, 2025, Stratus filed a response to an Office Action mailed June 4, 2025. On April 21, 2026, the Office mailed a Notice of Allowance. A copy of the April 21, 2026 Notice of Allowance is provided as Exhibit 2049 for the Board’s convenience. Attention is directed to pages 6-13 and 13-20[*] of Exhibit 2049, where the allowed claims are listed and the reasons for allowance over Racz and other references are stated, respectively.

[*] Page numbers for the exhibits discussed in this paper are PDF page numbers.

(f) U.S. Patent Application No. 19/272,521

This application is a continuation of U.S. Patent Application No. 17/190,224 and thus a grandchild continuation of the ’782 Patent under review in this IPR. On March 31, 2026, Stratus filed a response to an Office Action mailed December 31, 2025. On April 23, 2026, the Office mailed a final Office Action making only double-patenting rejections. Copies of Stratus’s March 31, 2026 Response and the April 23, 2026 Office Action are provided as Exhibits 2050 and 2051, respectively, for the Board’s convenience. Attention is directed to pages 2-17 of Exhibit 2050 (Stratus’s March 31, 2026 Response), where the claims are listed and pages 5-9 of Exhibit 2051 (the final Office Action), where reasons for allowance over Racz and other references are stated.

(g) Stratus Med., LLC v. Avanos Med., Inc., No. 1:25-cv-00546 (D. Del. filed May 2, 2025)

That litigation includes causes of action for infringement of the ’782 Patent by the petitioner. That litigation remains stayed pending this IPR and the ones noted in (a)-(c) above.

New Related Matters

In addition, the following new matters are identified:

(h) U.S. Patent Application No. 19/467,760

This application was filed February 2, 2026 as a continuation of U.S. Patent Application No. 18/378,138, and thus is a great grandchild continuation of the ’664 Patent under review in IPR2024-01212 and a great-great grandchild continuation of the ’688 Patent under review in IPR2024-01210 and IPR2024-01211.

(i) U.S. Patent Application No. 19/664,743

This application was filed April 30, 2026 as an application to reissue the ’668 Patent under review in IPR2024-01210 and IPR2024-01211. A copy of the reissue application as filed is provided as Exhibit 2052 for the Board’s convenience. Attention is directed to the following pages of Exhibit 2052:

- Pages 63-80, a claims listing in a preliminary amendment;
- Pages 81-85, Stratus’s remarks regarding the patentability of the claims;
- Pages 90-93, a Rule-132 declaration of Dr. Philip Finch, a co-inventor of the Racz reference, addressing Racz’s disclosure of needle sizes; and
- Pages 87-89, a Rule-132 declaration of Dr. Marc Russo, Stratus’s clinician expert witness, also addressing appropriate needle sizes for RF neurotomy.

Respectfully submitted,

Date: 2026 May 1

By: / M.C. Phillips /

Matthew C. Phillips
Registration No. 43,403

CERTIFICATE OF SERVICE

I hereby certify that on May 1, 2026, copies of the foregoing PATENT OWNER'S UPDATED MANDATORY NOTICES and all documents filed with it were served via electronic mail, as consented to by counsel, upon the following counsel for the petitioner:

Warren Thomas:	wthomas@mcciplaw.com
Gregory Carlin:	gcarlin@mcciplaw.com
Lee Hamilton:	lhamilton@mcciplaw.com

By: /M.C. Phillips/

Matthew C. Phillips
Reg. No. 43,403